Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: A 2-cohort, phase 2 study Academic Article uri icon

Overview

MeSH Major

  • Furans
  • Ketones
  • Ovarian Neoplasms
  • Tubulin Modulators

abstract

  • Eribulin produced an objective response in 5.5% of women with platinum-resistant, recurrent ovarian cancer and in 19% of women with platinum-sensitive disease. The median progression-free survival was 1.8 months in the platinum-resistant group and 4.1 months in the platinum-sensitive group.

publication date

  • May 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3245795

Digital Object Identifier (DOI)

  • 10.1002/cncr.26569

PubMed ID

  • 21935916

Additional Document Info

start page

  • 2403

end page

  • 10

volume

  • 118

number

  • 9